⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31394129 | 0.72 | — | — | |
| SCHEMBL30876261 | 0.67 | TP53 (0.42) | — | |
| SCHEMBL2928676 | 0.65 | — | — | |
| SCHEMBL2824063 | 0.62 | HRH4 (0.50) | — | |
| SCHEMBL29785697 | 0.61 | KDM4E (0.33) | — | |
| SCHEMBL28786363 | 0.61 | KDM4E (0.33) | — | |
| SCHEMBL20053998 | 0.61 | CCNA2 (0.45) | — | |
| SCHEMBL31015487 | 0.61 | PDE10A (0.36) | — | |
| SCHEMBL31014356 | 0.61 | PDE10A (0.36) | — | |
| SCHEMBL1085974 | 0.60 | CYP19A1 (0.42) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025054368-A1 | COMPOUNDS, COMPOSITIONS, AND METHODS | NICO THERAPEUTICS, INC. (US) | 2025-03-13 | — | — | WO | disclosed |
| US-20240083903-A1 | ARYL ETHER COMPOUNDS AS TEAD MODULATORS | MERCK SHARP & DOHME LLC (US) | 2024-03-14 | — | — | US | disclosed |
| EP-4294382-A1 | ARYL ETHER COMPOUNDS AS TEAD MODULATORS | Merck Sharp & Dohme LLC (US) | 2023-12-27 | — | — | EP | disclosed |
| CN-115594680-A | TEAD inhibitor | 武汉人福创新药物研发中心有限公司（CN） | 2023-01-13 | — | — | CN | disclosed |
| WO-2023280254-A1 | TEAD INHIBITOR | 武汉人福创新药物研发中心有限公司 | 2023-01-12 | — | — | WO | disclosed |
| WO-2022177869-A1 | ARYL ETHER COMPOUNDS AS TEAD MODULATORS | MERCK SHARP & DOHME LLC (US) | 2022-08-25 | — | — | WO | disclosed |
| EP-2934538-B1 | FACTOR IXA INHIBITORS | MERCK SHARP & DOHME (US) | 2021-03-31 | — | — | EP | disclosed |
| EP-3470409-B1 | BENZOTRIAZOLE-DERIVED ALPHA AND BETA-UNSATURATED AMIDE COMPOUND USED AS TGF-BETA RI INHIBITOR | GENFLEET THERAPEUTICS SHANGHAI INC (CN) | 2020-02-12 | — | — | EP | disclosed |
| US-10548883-B2 | Benzotriazole-derived α and β-unsaturated amide compound used as TGF-β RI inhibitor | GENFLEET THERAPEUTICS (SHANGHAI) INC. (CN) | 2020-02-04 | — | — | US | disclosed |
| US-20190151299-A1 | BENZOTRIAZOLE-DERIVED ALPHA AND BETA-UNSATURATED AMIDE COMPOUND USED AS TGF-BETA RI INHIBITOR | GENFLEET THERAPEUTICS SHANGHAI INC. (CN) | 2019-05-23 | — | — | US | disclosed |
| US-9708308-B2 | Factor IXa inhibitors | MERCK SHARP DOHME CORP. (US) | 2017-07-18 | — | — | US | disclosed |
| US-20150322056-A1 | Factor IXa Inhibitors | MOCHIDA PHARMACEUTICAL CO., LTD. (JP) | 2015-11-12 | — | — | US | disclosed |
| US-7045619-B2 | 2-(pyrazol-3-yl)carbapenem derivatives | SMITHKLINE BEECHAM P.L.C. (GB) | 2006-05-16 | — | — | US | disclosed |
| US-20030166923-A1 | 2-(pyrazol-3-yl)carbapenem derivatives | SMITHKLINE BEECHAM P.L.C. | 2003-09-04 | — | — | US | disclosed |
| EP-0725783-B1 | 2-(PYRAZOL-3-YL)CARBAPENEM DERIVATIVES | SMITHKLINE BEECHAM PLC (GB) | 2002-12-18 | — | — | EP | disclosed |
| US-20020147333-A1 | 2-(pyrazol-3-yl)carbapenem derivatives | SMITHKLINE BEECHAM P.L.C. | 2002-10-10 | — | — | US | disclosed |
| US-5612477-A | 2-(pyrazol-3-yl)carbapenem derivatives | SMITHKLINE BEECHAM P.L.C | 1997-03-18 | — | — | US | disclosed |
| US-5606051-A | 2-(pyrazol-3-yl)carbapenem derivatives | SMITHKLINE BEECHAM P.L.C. (GB) | 1997-02-25 | — | — | US | disclosed |
| EP-0725783-A1 | 2-(PYRAZOL-3-YL)CARBAPENEM DERIVATIVES | SMITHKLINE BEECHAM PLC (GB) | 1996-08-14 | — | — | EP | disclosed |
| WO-1995011905-A1 | 2-(PYRAZOL-3-YL)CARBAPENEM DERIVATIVES | SMITHKLINE BEECHAM PLC (GB) | 1995-05-04 | — | — | WO | disclosed |